Adenocarcinoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Frontline Ramucirumab Does Not Improve OS in Gastric Cancer - OncLive



OncLive
 
Frontline Ramucirumab Does Not Improve OS in Gastric Cancer 
OncLive
Adding ramucirumab (Cyramza) to cisplatin and capecitabine or 5-FU (5-fluorouracil) in the frontline setting did not improve overall survival (OS) in patients with HER2-negative metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma ...

 


F-fluorodeoxyglucose uptake predicts MET expression in lung adenocarcinoma - Dove Medical Press



F-fluorodeoxyglucose uptake predicts MET expression in lung adenocarcinoma 
Dove Medical Press
Objective: MET is a member of the receptor tyrosine kinases. Several MET-targeting inhibitors and antagonistic antibodies have shown promising data in clinical trials of lung adenocarcinoma. Finding noninvasive diagnostic tools to estimate the status ...

 


Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung ... - Dove Medical Press



Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung ... 
Dove Medical Press
Objective: To evaluate the efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma. Methods: A total of 53 advanced lung adenocarcinoma patients hospitalized between July 2013 and June ...

 


Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received ... - Dove Medical Press



Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received ... 
Dove Medical Press
There was no significant difference in overall survival between COPD and non-COPD groups (15.0 and 17.0 months, log-rank test p=0.57). In the multivariate Cox's proportional hazard model, the adjusted hazard ratio (HRadj) was statistically significant ...

 


Can keeping your teeth clean protect against oesophageal cancer? - NHS Choices



Can keeping your teeth clean protect against oesophageal cancer? 
NHS Choices
The oesophagus is the tube that takes food from the mouth to the stomach. Oesophageal cancer is becoming more common and around 8,900 people in the UK are diagnosed with it each year. There are two types of oesophageal cancer, oesophageal ...

and more » 


Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic ... - Dove Medical Press



Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic ... 
Dove Medical Press
Background: Pancreatic adenocarcinoma (PAC) is one of the most fatal cancers due to its high degree of malignancy, increasing incidence, high mortality, and unsatisfactory treatment efficacy. Evidence has suggested that numerous microRNAs (miRNAs ...

 


FDA approves first biosimilar for the treatment of certain breast and stomach cancers - FDA.gov



Moneycontrol.com
 
FDA approves first biosimilar for the treatment of certain breast and stomach cancers 
FDA.gov
The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose ...
FDA approves Ogivri, first biosimilar for certain breast, stomach cancers Healio
FDA Approves Biosimilar Trastuzumab for HER+ Breast Cancer Medscape
FDA Approves Eighth Biosimilar, First for Cancer Drug Herceptin Regulatory Focus
www.oncnursingnews.com/  -Markets Insider  -MPR  -MPR 
all 103 news articles » 


Wider sampling of tumor tissues may guide drug choice, improve outcomes - Science Daily



Wider sampling of tumor tissues may guide drug choice, improve outcomes 
Science Daily
The fourth cohort -- an ongoing trial known as PANGEA, Personalized ANtibodies for GastroEsophageal Adenocarcinoma designed by Catenacci and based at the University of Chicago Medicine -- included 28 patients. One focus of this trial was genetic ...

 


Epidemiology of ovarian cancers in Zaria, Northern Nigeria: a 10-year study - Dove Medical Press



Epidemiology of ovarian cancers in Zaria, Northern Nigeria: a 10-year study 
Dove Medical Press
There were 17 cases (22.3%) of aggressive cancers in patients aged ?20 years. A majority of the patients, 65 (83.3%), were parous with only nine (11.5%) patients being nulliparous. Serous cyst adenocarcinoma accounted for 32 (41%) cases. Granulosa ...

 


Bavencio Fails to Increase Survival of Advanced Gastric Cancer Patients in Phase 3 Trial - Immuno-Oncology News



Immuno-Oncology News
 
Bavencio Fails to Increase Survival of Advanced Gastric Cancer Patients in Phase 3 Trial 
Immuno-Oncology News
Bavencio (avelumab) failed to increase overall survival of unresectable, recurrent, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma patients in a Phase 3 trial, Merck KGaA and Pfizer announced. The JAVELIN Gastric 300 trial ...